Last reviewed · How we verify
Corticosteroid or NSAID
Corticosteroid or NSAID is a Corticosteroid or NSAID Small molecule drug developed by Hoffmann-La Roche. It is currently FDA-approved for Inflammatory and autoimmune disorders (corticosteroids), Pain and inflammation management (NSAIDs).
Corticosteroids suppress immune and inflammatory responses by binding glucocorticoid receptors, while NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin production and inflammation.
Corticosteroids suppress immune and inflammatory responses by binding glucocorticoid receptors, while NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin production and inflammation. Used for Inflammatory and autoimmune disorders (corticosteroids), Pain and inflammation management (NSAIDs).
At a glance
| Generic name | Corticosteroid or NSAID |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Corticosteroid or NSAID |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Pain Management |
| Phase | FDA-approved |
Mechanism of action
This entry represents two distinct drug classes with different mechanisms. Corticosteroids work systemically to dampen immune cell activation and cytokine production. NSAIDs act peripherally to block COX-1 and COX-2 enzymes, reducing inflammatory mediators and pain signaling. Both are used to manage inflammatory and autoimmune conditions, though through different pathways.
Approved indications
- Inflammatory and autoimmune disorders (corticosteroids)
- Pain and inflammation management (NSAIDs)
Common side effects
- Gastrointestinal bleeding or ulceration (NSAIDs)
- Immunosuppression and infection risk (corticosteroids)
- Hypertension
- Osteoporosis (chronic corticosteroid use)
- Cardiovascular events (NSAIDs)
Key clinical trials
- Ketorolac in Upper Extremity Tendinopathy and Arthropathy (PHASE4)
- Can Multimodal Medical Strategies Can Delay Total Knee Replacement? (NA)
- Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis (PHASE3)
- Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) (PHASE4)
- 3D Evaluation of Postoperative Edema After Third Molar Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid or NSAID CI brief — competitive landscape report
- Corticosteroid or NSAID updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Corticosteroid or NSAID
What is Corticosteroid or NSAID?
How does Corticosteroid or NSAID work?
What is Corticosteroid or NSAID used for?
Who makes Corticosteroid or NSAID?
What drug class is Corticosteroid or NSAID in?
What development phase is Corticosteroid or NSAID in?
What are the side effects of Corticosteroid or NSAID?
Related
- Drug class: All Corticosteroid or NSAID drugs
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Immunology, Rheumatology, Pain Management
- Indication: Drugs for Inflammatory and autoimmune disorders (corticosteroids)
- Indication: Drugs for Pain and inflammation management (NSAIDs)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing